Guest editorial:

HIGHLIGHT REPORT: THE EDI3-GPAM AXIS IN TUMOR CELL MIGRATION

Reham Hassan

Forensic Medicine and Toxicology Department, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt; Reham_Hassan@vet.svu.edu.eg

http://dx.doi.org/10.17179/excli2017-855

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

Recently, the glycerophosphodiesterase EDI3 (GPCPD1) has been shown to represent a key factor of choline metabolism that mediates tumor cell migration, adhesion and spreading (Stewart et al., 2012; Lesjak et al., 2014). EDI3 cleaves glycerophosphocholine to choline and glycerol-3-phosphate (Marchan et al., 2012). Choline is further metabolized by choline kinase alpha (CHKA) that generates phosphocholine. The second EDI3 product, glycerol-3-phosphate (G3P) is a substrate of glycerol-3-phosphate acyltransferase 1 (GPAM) that generates phosphatidic acid (PA). Currently, it remains unclear, whether the pathway via CHKA or GPAM (or both) is relevant for increased tumor cell migration.

Recently, the group of Rosemarie Marchan at Dortmund University has clarified this question (Marchan et al., 2017). The authors overexpressed and knocked down GPAM and CHKA in several ovarian cancer cell lines. Interestingly, they demonstrated that only manipulation of GPAM and not CHKA influenced cell migration. Moreover, silencing GPAM reduced the growth of mouse tumor xenografts (Marchan et al., 2017). High GPAM expression was also associated with worse prognosis in ovarian cancer patients. Therefore, the study of Marchan and colleagues clearly demonstrated that GPAM is the relevant enzyme downstream of EDI3 responsible for enhanced tumor cell migration.

Altered metabolism of tumor cells has been linked to progression and worse outcome in numerous studies (Currie et al., 2013; Pavlova and Thompson, 2016; Santos and Schulze, 2012). However, choline metabolism has attracted comparatively little attention (Glunde et al., 2015; Okazaki et al., 2010; Granata et al., 2014; Hu et al., 2016). Therapy and subtyping of carcinomas depends on the identification of factors influencing tumor prognosis (Heimes et al., 2017a, b; Hellwig et al., 2016; Stock et al., 2015: Cadenas et al., 2014: Sicking et al., 2014; Shakeri et al., 2016). The present study of Marchan and colleagues (2017) demonstrates that the EDI3-GPAM pathway in choline metabolism influences the tumor phenotype and prognosis, therefore justifying further research how exactly these enzymes link choline metabolism to tumor cell migration.

REFERENCES

Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014;13:3282-91.

Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61.

Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwalla ZM. Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn. 2015;15: 735–47.

Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, Ricci A, et al. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer. 2014; 110:330–40.

Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Elger T, et al. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. Breast Cancer Res Treat. 2017a; 165:293-300.

Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Gebhard S, et al. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J Cancer Res Clin Oncol. 2017b; 143:1123-31.

Hellwig B, Madjar K, Edlund K, Marchan R, Cadenas C, Heimes AS, et al. Epsin family member 3 and ribosome-related genes are associated with late metastasis in estrogen receptor-positive breast cancer and long-term survival in non-small cell lung cancer using a genome-wide identification and validation strategy. PLoS One. 2016;11:e0167585.

Hu L, Wang RY, Cai J, Feng D, Yang GZ, Xu QG, et al. Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. Oncotarget. 2016;7:66660–78.

Lesjak MS, Marchan R, Stewart JD, Rempel E, Rahnenführer J, Hengstler JG. EDI3 links choline metabolism to integrin expression, cell adhesion and spreading. Cell Adh Migr. 2014;8:499-508.

Marchan R, Lesjak MS, Stewart JD, Winter R, Seeliger J, Hengstler JG. Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities. Cell Cycle. 2012;11:4499-506.

Marchan R, Büttner B, Lambert J, Edlund K, Glaeser I, Blaszkewicz M, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma. Cancer Res. 2017;77: 4589-601.

Okazaki Y, Ohshima N, Yoshizawa I, Kamei Y, Mariggio S, Okamoto K, et al. A novel glycerophosphodiester phosphodiesterase, GDE5, controls skeletal muscle development via a non-enzymatic mechanism. J Biol Chem. 2010;285:27652–63.

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism.Cell Metab. 2016;23:27–47.

Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610–23.

Shakeri H, Gharesouran J, Fakhrjou A, Esfahani A, Mohaddes Ardebili SM. DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification. EXCLI J. 2016;15:11-20.

Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, et al. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One. 2014;9:e111306.

Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, Ellis JK, et al. Choline-releasing glycer-ophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A. 2012;109: 8155-60.

Stock AM, Klee F, Edlund K, Grinberg M, Hammad S, Marchan R, et al. Gelsolin is associated with longer metastasis-free survival and reduced cell migration in estrogen receptor-positive breast cancer. Anticancer Res. 2015;35:5277-85.